Recently, the SERCA inhibitor CAD204520 with reduced off-target toxicity has been established, which allows us to investigate the relevance of the NOTCH1 pathway and its therapeutic consequences in MLLr leukemia [26]. This evidence concerns the gene NOTCH1 and leukemia.